We start by offering products and contract services to the global life science research communities. Today we have established our technology and research development to support health care.
Redefining the Way
When Newlife BioChemEx registered in 2011, our goal was to support the life science research community through innovative research used reagents or services. However, after many years working in the life science field, we established our new technologies and moved to develop in vitro diagnostic tests. In addition, the most recent pandemic continually moved us towards clinical health care. As a result, we noticed the demand for POC diagnostics, which required rapid, straightforward, and high sensitivity. To address these requirements, we have started to develop a paper-based NAAT for POC diagnostics, which combines novel technologies.
We believe that rapid and accurate diagnosis can save lives by facilitating early treatment, saving money by preventing inappropriate treatment, preventing epidemics by minimizing viral transmission, and improving surveillance with additional early infection detection.
Our Journey So Far
DEVELOPING PAPER BASED NAAT
There are scientists who joined the company and initiated the development for paper-based NAAT for POC diagnostics.
DEVELOPING MULTIPLEX TEST ASSAYS
We proposed and received initial private fundings to support our development of a multiplex test assay to measure trace levels of IFNα in the initial phase of viral infections.